Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit After Tax
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
2,275.00
263.00
2,012.00
765.02%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
2,275.00
263.00
2,012.00
765.02%
Expenditure (Ex Depriciation)
Stock Adjustments
-488.00
0.00
-488.00
0%
Raw Materials Consumed
1,868.00
0.00
1,868.00
0%
Power & Fuel Cost
2.00
26.00
-24.00
-92.31%
Employee Cost
264.00
103.00
161.00
156.31%
Operating Expenses
20.00
25.00
-5.00
-20.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
124.00
1.00
123.00
12,300.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
31.00
3.00
28.00
933.33%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
2,013.00
214.00
1,799.00
840.65%
Operating Profit (PBDIT) excl Other Income
262.00
48.00
214.00
445.83%
Other Income
28.00
2.00
26.00
1,300.00%
Operating Profit (PBDIT)
290.00
51.00
239.00
468.63%
Interest
4.00
7.00
-3.00
-42.86%
Profit before Depriciation and Tax
286.00
43.00
243.00
565.12%
Depreciation
28.00
6.00
22.00
366.67%
Profit Before Taxation & Exceptional Items
257.00
37.00
220.00
594.59%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
252.00
29.00
223.00
768.97%
Provision for Tax
64.00
9.00
55.00
611.11%
Profit After Tax
187.00
19.00
168.00
884.21%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
632.00
1,018.00
-386.00
-37.92%
Profit Available for appropriations
820.00
1,038.00
-218.00
-21.00%
Appropriations
820.00
1,038.00
-218.00
-21.00%
Equity Dividend (%)
1800%
500%
1,300.00
Earnings Per Share
75.01
3.97
71.04
1,789.42%
Profit And Loss - Net Sales
Net Sales 2,275.58 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 32.59% vs 32.48% in Mar 2025
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 262.03 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 3.17% vs 37.69% in Mar 2025
Profit And Loss - Interest
Interest 4.49 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 207.53% vs 21.67% in Mar 2025
Profit And Loss - Profit After Tax
Profit After Tax 187.52 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 62.02% vs -28.34% in Mar 2025
